Evolution of the biopharmaceutics classification system (BCS) to oral modified release (MR) formulations; what do we need to consider?

European Journal of Pharmaceutical Sciences

Volumn 8, Issue 3, 1999, Pages 157-159

  Wilding, Ian R ^a  

^a PHARMACEUTICAL PROFILES LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ARTICLE; CONTROLLED DRUG RELEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; GASTROINTESTINAL TRACT; HUMAN; INTESTINE WALL; METABOLISM; ORAL DRUG ADMINISTRATION; PH; PRIORITY JOURNAL; STOMACH JUICE;

EID: 0033166674     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(99)00019-6     Document Type: Note

References (13)

1. Amidon, G.L., Lennernäs, H., Shah, V.P., Crison, J.R., 1995. A theoretical basis for a biopharmaceutic drug classification; the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413-420.
2. Corrigan, O.I., 1997. The biopharmaceutical drug classification and drugs administered in extended release (er) formulations. In: Young, et al. (Ed.), In Vitro-in Vivo Correlations, Plenum Press, New York.
3. Davis, S.S., Hardy, J.G., Fara, J.W., 1986. The intestinal transit of pharmaceutical dosage forms. Gut 27, 886-892.
4. Diletti, E., Hauschke, D., Steinijans, V.W., 1991. Sample size determination for bioequivalence assessment by means of confidence intervals. Int. J. Clin. Pharmacol. Ther. Toxicol. 29, 1-8.
5. TM capsule: A new easy to use approach for assessing regional drug absorption from the gastrointestinal tract. Pharm. Tech. Eur. 9 (6), 46-53.
6. Hussain, A.S., Kaus, L.C., Lesko, L.J., Williams, R.L., 1997. Analysis of NDA and ANDA data base for validation. Eur. J. Pharm. Sci. 5 (Suppl. 2), S43-S44.
7. Ishibashi, T., Pitcairn, G.R., Yoshino, H., Mizobe, M., Wilding, I.R., 1998. Scintigraphic evaluation of a new capsule-type colon specific drug delivery system in healthy volunteers. J. Pharm. Sci. 87, 531-535.
8. Lennernäs, H., Ahrenstedt, O., Hallgren, R., Knutson, L., Ryde, M., Paalzow, L.K., 1992. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm. Res. 9, 1243-1251.
9. Lennernäs, H., 1998. Human intestinal permeability. J. Pharm. Sci. 87, 403-410.
10. Lesko, L.J., 1997. Research to policy; evolution of the BCS in regulatory decision making. Eur. J. Pharm. Sci. 5 (Suppl. 2), S42.
11. Paine, M.F., Khalighi, M., Fisher, J.M., Shen, D.D., Kunze, K.L., Marsh, C.L., Perkins, J.D., Thummel, K.E., 1997. Characterization of inter-intestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharm. Exp. Ther. 283 (3), 1552-1562.
12. Read, N.W., Janabi, M.L., Bates, E.T., Barber, D.C., 1983. Effect of gastrointestinal intubation on the passage of a solid meal through the stomach and small intestine in humans. Gastroenterology 84, 1568-1572.
13. Rubas, W., Cromwell, M.E.M., Shahrokh, Z., Brabham, K., Mah, S., Delie, F., Nguyen, T.-N., 1997. Are Caco-2 cells predictive of transport and/or metabolic properties of mammalian intestinal tissues? Eur. J. Pharm. Sci. 5 (Suppl. 2), S13-S14.